Your Molecule
Your Molecule
How We Solve High-Concentration Challenges
How We Solve High-Concentration Challenges
Stable, patient-friendly injectable biologics — even above 200 mg/mL. We engineer high-concentration formulations that meet stability, viscosity and usability targets for subcutaneous (SC) delivery.
Early risk identification to design stable, patient-ready drug products
Why high concentration matters?
Why high concentration matters?
Subcutaneous administration shortens administration time, improves patient convenience and reduces healthcare burden — but it often pushes biologics above 100–200 mg/mL where viscosity, aggregation and processing issues can derail development. Our approach combines targeted experimental design with advanced data science to overcome these challenges early and chart a clear path to a stable, usable drug product.
Explore our full modalities hub
Subcutaneous administration shortens administration time, improves patient convenience and reduces healthcare burden — but it often pushes biologics above 100–200 mg/mL where viscosity, aggregation and processing issues can derail development. Our approach combines targeted experimental design with advanced data science to overcome these challenges early and chart a clear path to a stable, usable drug product.
Explore our full modalities hub
Subcutaneous administration shortens administration time, improves patient convenience and reduces healthcare burden — but it often pushes biologics above 100–200 mg/mL where viscosity, aggregation and processing issues can derail development. Our approach combines targeted experimental design with advanced data science to overcome these challenges early and chart a clear path to a stable, usable drug product.
Explore our full modalities hub
Our expertise
Our expertise
We structure each program into focused work-packages that answer the key feasibility and usability questions for SC dosing: formulation strategy, viscosity/injectability behavior, aggregation risks, and the molecule’s practical concentration ceiling. Decisions are underpinned by design-of-experiments (DoE) and predictive models to cut iteration and limit drug substance demand.
We structure each program into focused work-packages that answer the key feasibility and usability questions for SC dosing: formulation strategy, viscosity/injectability behavior, aggregation risks, and the molecule’s practical concentration ceiling. Decisions are underpinned by design-of-experiments (DoE) and predictive models to cut iteration and limit drug substance demand.
We structure each program into focused work-packages that answer the key feasibility and usability questions for SC dosing: formulation strategy, viscosity/injectability behavior, aggregation risks, and the molecule’s practical concentration ceiling. Decisions are underpinned by design-of-experiments (DoE) and predictive models to cut iteration and limit drug substance demand.
Ready to talk about your bispecific formulation strategy?
Ready to talk about your bispecific formulation strategy?
Turning complex molecules into robust drug products
Key Focus Areas
-
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Case Study
Up-concentrating an antibody using a standard formulation does not always result in a stable drug product. The up-concentrated commercially available formulation (red) is significantly less stable as it results in a drastically increased rate of aggregation. In comparison, Leukocare’s HighCon antibody formulation (blue) achieved a 2-fold higher concentration while stably preventing any increase in aggregate formation over time.
Case Study
Up-concentrating an antibody using a standard formulation does not always result in a stable drug product. The up-concentrated commercially available formulation (red) is significantly less stable as it results in a drastically increased rate of aggregation. In comparison, Leukocare’s HighCon antibody formulation (blue) achieved a 2-fold higher concentration while stably preventing any increase in aggregate formation over time.